Travere Therapeutics (TVTX) Interest & Investment Income (2013 - 2026)

Travere Therapeutics has reported Interest & Investment Income for 14 years, with the latest figure at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 31.91% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $11.5 million (down 26.12% YoY), and the FY2025 full-year result was $12.7 million, down 28.6% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $2.6 million, roughly flat from $2.6 million in the prior quarter.
• The five-year high for Interest & Investment Income was $14.4 million in Q4 2022, with the low at -$2.8 million in Q3 2022.
• Historically, Interest & Investment Income has averaged $3.8 million across 5 years, with a median of $3.6 million in 2023.
• Annual changes were most pronounced in 2022 — Interest & Investment Income plunged 885.83% — and 2023, when it soared 555.75%.
• Travere Therapeutics' Interest & Investment Income stood at $14.4 million in 2022, then plunged by 50.44% to $7.2 million in 2023, then plunged by 46.94% to $3.8 million in 2024, then slumped by 31.7% to $2.6 million in 2025, then decreased by 0.31% to $2.6 million in 2026.
• The last three Interest & Investment Income figures came in at $2.6 million (Q1 2026), $2.6 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.